Clinical Trial Update: CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 trial update for CF101 therapy in patients with moderate-to-severe plaque psoriasis has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• CF101 (piclidenoson)

Snippet

Sponsor: Can-Fite BioPharma | Conditions: Plaque Psoriasis | Phase 3 | Status: COMPLETED